Profile data is unavailable for this security.
About the company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.
- Revenue in USD (TTM)3.47bn
- Net income in USD324.37m
- LocationIncyte Corp1801 Augustine Cut-OffWILMINGTON 19803United StatesUSA
- Phone+1 (302) 498-6700
- Fax+1 (302) 636-5454
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|INCY:NSQ since |
|Villaris Therapeutics Inc||Announced||03 Oct 2022||03 Oct 2022Announced||-6.09%||1.43bn|